P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)
February 11, 2020
P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.
- Buyers
- P4 Diagnostix
- Targets
- Strand Diagnostics
- Sellers
- Strand Diagnostics
- Industry
- Healthcare Services
- Location
- Indiana, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Fulgent Genetics to Acquire Bako Diagnostics and StrataDx
December 22, 2025
Healthcare Services
Fulgent Genetics entered into a definitive agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx for a combined purchase price of approximately $55.5 million, subject to adjustments. The acquisitions are expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals.
-
Ginkgo Bioworks Acquires Proof Diagnostics
February 28, 2024
Biotechnology
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
Quest Diagnostics Acquires Haystack Oncology
April 27, 2023
Healthcare Services
Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp has completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a cancer genomics company focused on liquid biopsy and tissue-based genomic products and services. The deal builds on and expands Labcorp’s oncology and next-generation sequencing (NGS) capabilities and liquid biopsy offerings.
-
JMD Properties, Inc. Acquires Stella Diagnostics
September 2, 2020
Biotechnology
JMD Properties, Inc. announced the acquisition of Stella Diagnostics, LLC via a preferred stock transaction and will change its corporate name to Stella Diagnostics, Inc. The deal positions the public company to pivot into the molecular diagnostics / biotech sector to commercialize Stella’s oncology-focused assays for esophageal disease.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.